Cash burners can fire outstanding returns

By James Henderson

While balance sheet discipline is often a welcome feature of a potential investment, occasionally it pays to consider businesses that are spending cash on themselves, as we have done for Lowland Investment Company.

Listen to any fund manager presentation and the core script will almost invariably include lines like this: “We buy strong, growing companies that are generating lots of cash and have strong balance sheets and barriers to competition… Blah, blah…”

Well, perhaps not “Blah, blah…” ­– but you get the gist. It would be nice to hear a manager say that sometimes they include in their portfolio companies burning cash so fast that without an urgent injection of capital they face ruin.

You might ask why on earth anyone would want such a company, but many of the best investments I have ever made have fallen into this category. One of our best performers this year has been Rolls-Royce, which is up 140% so far.

This is a company that in January was described by its new boss as a “burning platform”. Tufan Erginbilgic pointed to the disappointing returns made on invested capital and set about changing things.

He has sold off non-core businesses – one of the largest being the €1.8bn disposal of Spanish joint venture ITP Aero. He has focused spending on priority areas and renegotiated maintenance contracts.

Post-Covid recovery in air transport has helped. The combination means that in just the first six months of the year operating margins soared from 3.4% to 12.4% and the company generated twice as much profit as analysts were expecting – £673m.

Those earlier analyst forecasts have shown how a gloomy mindset can set in around a company. Rolls-Royce was certainly not one for investors who only like companies with attractive cash flows. They have missed out.

Unearthing these opportunities takes research. Often you are looking for yesterday’s leaders in recovery, like Rolls-Royce. But more usually you find them in smaller companies. When investing in these businesses you must always be aware that at some point you may be touched for more cash – or see your shares diluted. It is called a “rights issue”.

It is easy to forget that the purpose of the stock exchange is to help companies raise capital. In return they offer a stake in the business and a share of all future profits for as long as the company operates and those shares are in operation.

Companies can seek to raise cash for all sorts of reasons. In the AIM market it would usually be to build new plant, expand production or take a new product from prototype to production. Examples in our portfolio include alternative energy companies such as AFC, ITM and Ceres. These are still fairly early-stage businesses but could have enormous potential as we move to a low-carbon world.

Sometimes companies can experience a cash squeeze because of events, like Covid. For investors who support any fund-raising endeavours the hope may be that if the business can get through to the other side of the crisis it will find competition weakened and gain significant market share.

One of the most memorable examples of a company raising capital because of a crisis was in 2001. Following the terrorist attack on the Twin Towers in New York, insurer Hiscox came to the market twice – in 2001 and 2002 – seeking around £164m. We backed it. With that money it was able to write new business at an attractive rates, because many of its competitors were out of the market in light of their own cash struggles. It helped enable Hiscox, then a relatively small business, to step into the big leagues. The rights issue shares were £1.20 and £1.65. Today Hiscox shares trade at more than £10.

There is heightened risk in cash burning investments, but risks can be mitigated. We want to understand clearly what is behind the cash burn and how quickly investment might be expected to pay off. Is it a Covid-style crisis and a story of the fittest survivor thriving when normal service resumes?

A crucial question we ask ourselves is how much we trust management. Often new management will launch a rights issue as part of a big reorganisation plan. Does that plan excite us? Can we see the potential or is it pouring good money after bad?

It might be that the plan is not articulated well and is not convincing. It might be that we do not have confidence in management’s ability to execute it. In such cases we may not just decline to pay up – we may sell our shares altogether. Sometimes it is better to take your losses and move on, putting your money to work in more promising areas.

Of course, we have had failures, but when you get the decision right the rewards from a cash burner can far outpace those offered by the majority of healthy cash generators that can form the core of portfolios.

Find out more here


Important information

References made to individual securities do not constitute a recommendation to buy, sell or hold any security, investment strategy or market sector, and should not be assumed to be profitable. Janus Henderson Investors, its affiliated advisor, or its employees, may have a position in the securities mentioned.

Not for onward distribution. Before investing in an investment trust referred to in this document, you should satisfy yourself as to its suitability and the risks involved, you may wish to consult a financial adviser. This is a marketing communication. Please refer to the AIFMD Disclosure document and Annual Report of the AIF before making any final investment decisions. Past performance does not predict future returns. The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested. Tax assumptions and reliefs depend upon an investor’s particular circumstances and may change if those circumstances or the law change. Nothing in this document is intended to or should be construed as advice. This document is not a recommendation to sell or purchase any investment. It does not form part of any contract for the sale or purchase of any investment. We may record telephone calls for our mutual protection, to improve customer service and for regulatory record keeping purposes.

Issued in the UK by Janus Henderson Investors. Janus Henderson Investors is the name under which investment products and services are provided by Janus Henderson Investors International Limited (reg no. 3594615), Janus Henderson Investors UK  Limited (reg. no. 906355), Janus Henderson Fund Management UK Limited (reg. no. 2678531), (each registered in England and  Wales at 201 Bishopsgate, London EC2M 3AE and regulated by the Financial  Conduct Authority) and Janus Henderson Investors Europe S.A. (reg no. B22848 at 2 Rue de Bitbourg, L-1273, Luxembourg and regulated by the Commission de Surveillance du Secteur Financier).

Janus Henderson and Knowledge Shared are trademarks of Janus Henderson Group plc or one of its subsidiaries. © Janus Henderson Group plc

These are the views of the author at the time of publication and may differ from the views of other individuals/teams at Janus Henderson Investors. References made to individual securities do not constitute a recommendation to buy, sell or hold any security, investment strategy or market sector, and should not be assumed to be profitable. Janus Henderson Investors, its affiliated advisor, or its employees, may have a position in the securities mentioned.

Past performance does not predict future returns. The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested.

The information in this article does not qualify as an investment recommendation.

Marketing Communication.

Glossary

Balance sheet

A financial statement that summarises a company’s assets, liabilities and shareholders’ equity at a particular point in time. Each segment gives investors an idea as to what the company owns and owes, as well as the amount invested by shareholders. It is called a balance sheet because of the accounting equation: assets = liabilities + shareholders’ equity.

Barriers to entry

Factors that can prevent or hinder new competitors from entering into an industry or business area, such as high start-up costs, patents, technical knowledge, brand loyalty etc.

Capital

When referring to a portfolio, the capital reflects the net asset value of a fund. More broadly, it can be used to refer to the financial value of an amount invested in a company or an investment portfolio.

Free cash flow (FCF)

Cash that a company generates after allowing for day-to-day running expenses and capital expenditure. It can then use the cash to make purchases, pay dividends or reduce debt.

AIM movers: LungLife AI validates lung cancer test and Plexus licence deal

2

LungLife AI Inc (LON: LLAI) has successfully validated its LungLB early lung cancer detection test. The positive predictive value was 81% in distinguishing cancer nodules smaller than 15mm. The current standard is 60%. There will be an early access programme offered in the first quarter of 2024. The test will be optimised for additional uses. The share price initially rose above 70p and it is currently 30.4% ahead at 60p.

Sareum (LON: SAR) says that its co-development partner CRT Pioneer Fund has entered into a development and commercialisation licence for SRA737 with a US biopharmaceutical company. SRA737 is an oral, selective checkpoint kinase 1 inhibitor that targets cancer cell replication. There will be an upfront payment of $500,000 to CRT Pioneer Fund with potential for an additional fee of up to $1m in cash and 500,000 shares. There could be payments of up to $289m if a successful drug is developed, plus high single-digit royalties. The share price jumped 21.9% to 72.5p.

Extractions Premium & Mining has converted £250,000 of loan notes in oil and gas explorer Corcel (LON: CRCL) at 0.8p/share. That leaves a balance of £750,000. Corcel executive chairman Antoine Karam owns 45% of Extractions Premium & Mining. The share price improved 18.3% to 0.81p.

Drug development services provider Proteome Sciences (LON: PRM) has completed the installation of equipment at its new laboratory in San Diego, which will service growing demand in the US.

Oriole Resources (LON: ORR) expects execution of the earn-in agreements with BCM for the Mbe and Bibemi gold exploration projects in Cameroon to happen this month. That will trigger payments of $1m and $450,000 respectively. BCM will then spend $4m on exploration to earn 50% of each of the projects. Managem has decided not to invest any more cash in the Senala project in Senegal, so Oriole will retain ownership of Senala. After an initial fall, the share price moved up 3.09% to 0.17525p.

FALLERS

Plexus Holdings (LON: POS) has extended an IP licence agreement with SLB, which replaces a previous surface production wellhead licence agreement with a subsidiary of SLB. For $5.2m in cash, SLB gets a licence in perpetuity to use POS-GRIP technology, including HG sealing technology. This licence covers areas of the market that are not a focus of Plexus. The 2023-24 revenues forecast has been upgraded to £14m and pre-tax profit raised by 467% to £1.7m. Net cash should be £3.8m at the end of June 2024. However, this is a one-off, so Plexus could fall back into loss next year. Plexus was the best AIM performer in 2023. The share price slipped 17.9% to 17.25p.

A general meeting has agreed to change the name of Barkby Group (LON: BARK) to Roadside Real Estate, which will be LON:ROAD. Barkby is refinancing its debt and a change to the articles of association will enable more to be borrowed. The share price declined 5.51% to 6p.

Real-time oil condition analysis company Tan Delta Systems (LON: TAND) says that progress has been slower than hoped since floating in August. Full year revenues will decline from £1.6m to £1.44m, which is lower than expected. Customer trials have been delayed, but there has been greater interest in the technology. The loss will be in line with expectations at £400,000. Cash was £4.5m at the end of the year. The placing price was 26p. The share price fell 4.35% to 22p.

Tekcapital’s Belluscura set for a landmark year

Tekcapital portfolio company Belluscura is positioned for a landmark 2024.

The stars are aligning for the developer and manufacturer of portable oxygen units after securing interest and orders totalling up to a potential $85m last year.

In addition, the company is on the verge of completing an innovative funding package designed to meet the demands of burgeoning orders in Asia.

The company has received approval in Singapore, Hong Kong, and, most recently, China. China represents a market of up to 100 million suffering from COPD.

“We are delighted to have received approval in China which has taken over approximately 10 months. This enables us to launch sales into China with immediate effect,” said Bob Rauker, Chief Executive Officer of Belluscura when the company released a trading update in December.

“With our arrangement with InnoMax in place, we are confident that we can now deliver on the significant potential for our products in this large and growing market.

“The approval in China, Singapore and Hong Kong are the first steps in leveraging the InnoMax agreement to expand in the ASEAN region and to distribute our portable oxygen concentrators in new markets, enhancing the lives of those with COPD and building market share in the process.

“Building any start up business is never easy, particularly within the MedTech world and in the current economic environment. After two years of testing, developing and refining our products, the Board is very confident that Belluscura is now well placed to take advantage of the significant opportunities it has in 2024 and beyond.”

This year is likely to be the year Belluscura transitions from the ‘start up’ phase Rauker mentioned, to a scale up multinational organisation generating significant revenues.

Belluscura’s lowly £35m market capitalisation may start to look excellent value as the company builds momentum.

The company was founded by Tekcaptial (LON:TEK), who retain a circa 10% stake. Tekcapital recently said they were continuing to progress with another AIM IPO from their stable of technology companies, MicroSalt.

MicroSalt has won substantial contracts with the world’s largest snack food companies and like Belluscura, is set for a year of multi-million pound revenue generation.

Why companies left AIM in November 2023

There were nine companies leaving AIM in November. Four were taken over, three got into financial difficulties, one decided to cancel its quotation and one decided to go into liquidation and distribute investments and cash to shareholders. There were no new admissions during the month.
3 November
Global Invacom
Satellite communications equipment provider Global Invacom gained shareholder approval for the cancellation of the AIM quotation. The shares are still traded on the Main board of the Singapore Exchange Securities Trading Ltd. A lack of liquidity and access to capital, plus duplicated co...

Growth: Keeping track of vessels on the seas

This company already has most of its forecast revenues for 2024 in the bag with annualised recurring revenues nearly as high as the forecast. It remains loss making but has a substantial cash buffer that is more than enough to ensure that the business reaches profitability before it runs out. That could happen by the end of 2025.
The company has confirmed that the 2023 results will be comfortably in line with forecasts. Demand for the company’s services is growing on the back of increasing sanctions activity in global trade.
Maritime AI technology services provider Windward (LON: WNWD) has bee...

AIM new admission: Gas prospects in the UK Irish Sea Basin

Standard list shell Dial Square Investments moved to AIM at the same time as the reverse takeover of EnergyPathways and it subsequently changed its name to the latter. The original intention was to seek a sports management business, but instead it acquired a developer of UK gas assets.
The focus is near-term, low emission energy and it has an interest in a block in the UK Irish Sea Basin. This could help to provide energy security for the UK. The cash raised will fund initial field development before the drilling of wells.
The shares had been suspended at 3.25p and they ended the first day of ...

Growth: Bundling payments

This company may have finally reached the point where it will become highly profitable. It has been on AIM for two decades and has made a small profit in one year. Cash has been pouted into developing the technology and it appears it is just about to pay off.
There was a first half loss, but this could be turned into a profit for 2023. Then, next year the profit is forecast to soar. It is possible that the forecast proves too optimistic, but the trend should still be true. The high operational gearing of the company means that if the revenues are growing the profit will grow faster once breake...

Aquis weekly movers: Western Selection returning cash

Western Selection (LON: WESP) has sold its liquid investments and it has £14.55m in the bank. It has illiquid investments in Industrial and Commercial Holdings and City Group are in the books for £46,000. The investment company is returning 80.5p/share in cash to shareholders and withdrawing from the Aquis Stock Exchange. The other investments will eventually be sold. Shareholders will be given the option to retain shares until the other investments are sold. The share price jumped 47.1% to 62.5p.

TruSpine Technologies (LON: TSP) reported an interim cash outflow from operating activities of £80,000, down from £508,000 in the corresponding period. There was net debt of £277,000 at the end of September 2023. Discussions continue with Spartan Medical concerning a new redistribution contract. The share price is 13.6% higher at 1.25p.

Marula Mining (LON: MARU) has completed phase 1 exploration activities at Nyorinyori and NyoriGreen projects. An initial report will be received in January. This, combined with assay results, will help to plan phase 2 of the exploration in the first quarter of 2024. The share price improved 7.14% to 13.125p.

KR1 (LON: KR1) had net assets of 76.56p/share at the end of November 2023. The income from digital assets during the month was £939,000. The share price increased 1.66% to 92p.

FALLERS

Tap Global Group (LON: TAP) generated trading revenues of £1.68m, based on trading payment volumes of £181.6m, taking total revenues to £2.02m in the year to June 2023. Revenues for the most recent five-month period were £1m. The company is still losing money. There was £2.3m in the bank at the end of June 2023. Tap Global plans to launch its cryptocurrency app in the US in the first quarter of 2024. The share price fell 4.88% to 1.95p.

Income: Strong track record of payments

Cyclical companies can also be steady dividend payers if boards grow the dividend in a sustainable way instead of in line with the movement in earnings, which can change rapidly because of operation gearing. This company currently has a dividend that is covered 2.3 times by forecast earnings. The shares are yielding nearly 5.7%.
In 20 years, this company has paid 76.2p/share in dividends, even before the latest payment. That is more than the current share price. The dividend payment was much higher back in 2008 and payments did stop in 2013 and 2014 when there was significant debt, but the bal...

AIM weekly movers: Cautious optimism at WH Ireland

10

AIM broker WH Ireland (LON: WHI) is seeing signs of improvement with underlying monthly profitability achieved in November 2023 thanks to cost cutting and there was cash of £6.8m. Annualised cost savings of £3.8m have been made. The underlying interim loss doubled to £1.8m with revenues dropping from £14.3m to £10.7m.  The share price jumped 64.3% to 5.75p.

Horizonte Minerals (LON: HZM) has secured a $20m interim funding package provided by major shareholders Orion, Glencore and La Mancha. Interest payments are being deferred by existing senior lenders. Management is reviewing the long-term project funding requirements for the Arafuaia nickel project. Full funding is targeted for the middle of 2024. The share price recovered 40.1% to 11p.

Donald Hamilton has taken a 3.04% stake in MyHealthChecked (LON: MHC). The share price improved 35.9% to 13.25p.

Trading in Enwell Energy (LON: ENW) has been restored following publication of interims to June 2023. The oil and gas producer had to replace its auditor. Interim revenues slumped from $77.2m to $33.1m and pre-tax profit fell from £42.8m to £17.4m. Following a 15p/share dividend, there was cash of $33.8m at the end of June 2023. The share price rose 28.5% to 16.9p.

FALLERS

Shares in fabless semiconductor developer Sondrel (LON: SND) were hit by a trading warning that flagged delays in development and payments and a subsequent shortage of cash. Sondrel expected a £1.7m payment from an automotive component manufacturer, but this will not be received until next year. Additional resources will be required to complete the project. Directors and staff have agreed to defer salaries because Sondrel cannot afford to pay them. More capital will be required by the end of March or earlier if the delayed payments are not made as early as expected. The share price partially recovered at the end of the week, but it was still down 40.1% to 4.85p because of the fundraising concerns.

Africa-focused agricultural company Agriterra (LON: AGTA) reported a decline in interim revenues from $4.96m to $3.58m and the loss increased from $1.35m to $1.6m. There was a cash outflow of more than $2.6m. Net debt was $12.7m at the end of September 2023. There is not enough grain in storage for the second half, so additional imports are required. The share price slumped 37.5% to 0.75p.

Tern (LON: TERN) investee company Device Authority has secured $7.3m in funding, with $4m already. The rest requires regulatory approvals. There will also be $2.1m loan notes converted into shares at the issue price. Tern had a 53.8% shareholding in the identity management technology developer and will convert $1m of loan notes. Device Authority will repay the $175,000 loan from Tern, which will have a diluted stake of 29.5% after the full fundraising. That is valued at £5.9m.  The Tern share price dipped 20.6% to 3.375p.

Autonomous drilling rig developer Tribe Technology (LON: TRYB) has not completed the latest drill rig due to technical issues and it will be delayed until the first quarter of 2024. It should be shipped to the customer by the summer. This means that revenues may be delayed until the next financial year. A field trial of the sample potting and handling system has been postponed. The 5 September placing price was 10p and the share price has declined 14.3% to 8.25p. There is £3.34m in cash left.